Pancreatic ductal adenocarcinoma (PDAC) is defined by a dense, immunosuppressive tumor microenvironment (TME) enriched with extracellular matrix components, cancer-associated fibroblasts (CAFs), and diverse immune populations. ChIP-seq analysis of resected human PDAC identified MICAL2 as a super-enhancer–associat...
Bharti Garg, E. Mose, Briana Nyugen et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely due to rapid development of resistance to standard chemotherapies such as gemcitabine. MICAL2 is a redox-dependent regulator of actin dynamics that is overexpressed in PDAC, but its role in therapeutic resistance remains poorly un...
Ponmathi Panneerpandian, Kevin Christian Montecillo Gulay, M. Macdonald et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...
K. Gulay, A. Martsinkovskiy, A. Lowy et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.